article thumbnail

STAT+: Oncologists more likely to provide low-value care after receiving pharma money, study finds

STAT

Oncologists were more likely to provide low-value cancer care after receiving money from pharmaceutical companies, and the findings raise questions about the extent to which industry influence may have led to patient harm, according to a new study. Continue to STAT+ to read the full story…

article thumbnail

The Issue with Reissue: PTE Edition

FDA Law Blog: Biosimilars

In the generic filers view, the regulatory review period should have started in January 2014 when the patent was reissued rather than in April 2004, when the IND was opened, because the reissued patent did not exist in April 2004. The plain text of 35 U.S.C. The Court thus explained that interpreting the patent in 35 U.S.C.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Novo Nordisk moves to strengthen obesity efforts

pharmaphorum

“Combining EraCal’s phenotypic screening platform with Novo Nordisk’s expertise within pharmaceutical peptides and metabolic diseases will contribute to the discovery of novel drug candidates for the treatment of obesity,” said Josua Jordi, CEO of EraCal. “We

Diabetes 123
article thumbnail

Pharmaceutical Negotiations Decoded: Lessons from the Trenches

Drug Patent Watch

Key Stakeholders in Pharmaceutical Negotiations Successful negotiations in the pharmaceutical industry require a deep understanding of the various stakeholders involved. These may include: Pharmaceutical companies (big pharma and biotech firms) Contract research organizations (CROs) Regulatory bodies (e.g.,

article thumbnail

Increasing patient engagement with UK clinical trials

pharmaphorum

Pharmaceutical companies often struggle to actively involve patients in the design phase of clinical trials but doing so can have huge benefits for the sustainability and success of research. In 2014 Keith was fortunate to become a full-time salaried patient research ambassador at Liverpool Heart and Chest Hospital Trust.

article thumbnail

Speaking of Medicine – Mid-Year OPDP Enforcement Review

Eye on FDA

There are two means of gaining insight into the agency’s thinking about regulatory issues related to promotional communications by pharmaceutical companies; one is through the issuance of guidance documents, the other is through enforcement. But when it comes to enforcement things have changed greatly over the years.

article thumbnail

Cancer researchers unable to access clinical trial data for top-selling drugs, study finds

The Guardian - Pharmaceutical Industry

The authors of a study published in the journal JAMA Oncology on Friday said the lack of transparency should be concerning to Australia. Sign up to receive an email with the top stories from Guardian Australia every morning Continue reading.